Protocol Ledger

NCT04248465 · Phase III · TERMINATED

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Interventional Phase III clinical trial protocol NCT04248465 sponsored by AstraZeneca in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-30 Enrollment: 382 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04248465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)382 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04248465
Protocol FieldVerified Registry Value
NCT IdentifierNCT04248465
Consolidated Lead SponsorAstraZeneca
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment382 participants (ACTUAL)
Registered Start Date2020-03-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI